Merck & Co. and NicOx Extend Research Collaboration
News Nov 03, 2005
NicOx S.A. has announced the extension of its research collaboration agreement with Merck & Co., Inc.
The purpose of the agreement, signed in August 2003, is to jointly evaluate selected proprietary NicOx nitric oxide-donating compounds in an undisclosed therapeutic area.
While the research was initially focused on one class of compounds, the two companies have agreed to broaden the field of investigation based on joint pre-clinical work conducted to date.
Additional pre-clinical studies will be initiated to identify potential lead candidates for development. Merck will make a payment to NicOx in connection with this extension of the agreement.
Merck exercised its exclusive option to negotiate for a license, development and commercialization agreement during the second quarter of 2005.
Michele Garufi, Chairman and CEO of NicOx, commented, “We look forward to continuing our collaboration with Merck. We are very pleased with the progress of this important research program, which suggests that nitric oxide-donation could provide potential benefits in an area of considerable medical need.”
“The conclusion of any future licensing agreement is of course dependent on successful results from the new research program and the agreement of contractual terms. NicOx and Merck expect to conclude this process during 2006.”
Helping people with addictions has become a research passion for Purdue University researchers who is leading a team to make drug discoveries to support millions around the world dealing with alcohol use disorders, chronic pain and mood disorders. The team's recent discovery provides a new avenue for the development of medications that provide therapeutic relief for a patient without causing unwanted side effects.READ MORE
3rd International Conference and Exhibition on Nanomedicine and Drug Delivery
Mar 13 - Mar 14, 2019